About toripalimab
PD-1 immune checkpoint inhibitor
Used for
- Treats certain cancers, including nasopharyngeal cancer and esophageal squamous cell carcinoma, depending on local approval and treatment regimen.
Usual adult dose
Usually 240 mg intravenously every 3 weeks; some regimens use 3 mg/kg every 2 weeks.
Common side effects
- Fatigue, rash, itching, or fever
- Diarrhea, nausea, or reduced appetite
- Thyroid hormone changes
- Immune-related inflammation of the lungs, bowel, liver, kidneys, or other organs
Important warnings
- Immune reactions can affect organs during treatment or after it ends.
- Report breathing difficulty, severe diarrhea, yellow skin, or unusual weakness promptly.
- May require treatment interruption and corticosteroids for serious immune reactions.
- Use only under specialist supervision for approved cancer indications.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least 4 months after the last dose.
Breastfeeding
Avoid breastfeeding during treatment and for at least 4 months after the last dose.
Interactions
- No major direct drug interactions are established; immune effects may complicate other treatments.
- Tell the oncology team about immunosuppressants, including corticosteroids, and all other medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.